These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4013413)

  • 1. [Immunologic reactions following influenza virus vaccination].
    Süss J; Schmidt S; Groh A; Vogt KH; Schmidt J
    Z Gesamte Hyg; 1985 Mar; 31(3):149-53. PubMed ID: 4013413
    [No Abstract]   [Full Text] [Related]  

  • 2. [Preventive influenza vaccination].
    Glathe H
    Z Arztl Fortbild (Jena); 1990; 84(8):377-80. PubMed ID: 2378120
    [No Abstract]   [Full Text] [Related]  

  • 3. [Circulating and secretory antibodies in mice after administration of influenza virus by various routes].
    Wilczyński J; Loza-Tulimowska M; Semkow R
    Med Dosw Mikrobiol; 1979; 31(4):239-44. PubMed ID: 544981
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative efficacy of influenza vaccines.
    Linder J
    N Engl J Med; 2010 Jan; 362(2):180; author reply 180-1. PubMed ID: 20077593
    [No Abstract]   [Full Text] [Related]  

  • 5. Valuable data surrounding the priming and boosting abilities of various vaccine technologies.
    Toback S; Ambrose C
    Vaccine; 2009 Jan; 27(3):349. PubMed ID: 19027811
    [No Abstract]   [Full Text] [Related]  

  • 6. Mucosal vaccination against influenza: protection of pigs immunized with inactivated virus and ether-split vaccine.
    Lim YK; Takada A; Tanizaki T; Ozaki H; Okazaki K; Kida H
    Jpn J Vet Res; 2001 Feb; 48(4):197-203. PubMed ID: 11276584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination against influenza in the elderly. Experience with adjuvant vaccines].
    Baldo V; Menegon T; Buoro S; Scalici C; Vesco A; Perale S; Boato W; Carletti M; Bonello C; Dalla Costa D; Trivello R
    Ann Ig; 1999; 11(5):369-74. PubMed ID: 10596424
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.
    Avtushenko SS; Sorokin EM; Zoschenkova NY; Zacharova NG; Naichin AN
    J Biotechnol; 1996 Jan; 44(1-3):21-8. PubMed ID: 8717382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of influenza vaccines.
    Narayan KM; del Rio C
    N Engl J Med; 2010 Jan; 362(2):179-80; author reply 180-1. PubMed ID: 20071712
    [No Abstract]   [Full Text] [Related]  

  • 10. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients.
    Vogtländer NP; Brown A; Valentijn RM; Rimmelzwaan GF; Osterhaus AD
    Vaccine; 2004 Jun; 22(17-18):2199-201. PubMed ID: 15149777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients.
    Lindemann M; Witzke O; Lütkes P; Fiedler M; Kreuzfelder E; Philipp T; Roggendorf M; Grosse-Wilde H
    Clin Immunol; 2006 Sep; 120(3):342-8. PubMed ID: 16631409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of a live attenuated influenza B virus vaccine candidate.
    Seo SU; Byun YH; Lee EY; Jung EJ; Jang YH; Kim HA; Ha SH; Lee KH; Seong BL
    Vaccine; 2008 Feb; 26(7):874-81. PubMed ID: 18207290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
    Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
    J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Problems of specific secretory antiviral immunity].
    Shvartsman IaS
    Usp Sovrem Biol; 1976; 81(3):429-44. PubMed ID: 788388
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.
    Belshe R; Lee MS; Walker RE; Stoddard J; Mendelman PM
    Expert Rev Vaccines; 2004 Dec; 3(6):643-54. PubMed ID: 15606348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is there a paraspecific effect of influenza vaccination?].
    Maiwald H; Bock HL; Schleich T; Zerban R; Stickl H
    Zentralbl Hyg Umweltmed; 1989 Nov; 189(2):185-91. PubMed ID: 2532514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory.
    Wright PF; Murphy BR; Kervina M; Lawrence EM; Phelan MA; Karzon DT
    Infect Immun; 1983 Jun; 40(3):1092-5. PubMed ID: 6852914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.